Moreover, EZH2 has received attention as a target for cancer treatment because EZH2-mediated tri-methylation of histone H3K27 results in inactivation of tumor suppressor genes such as PSP94 and p16INK4a [16–18]. Here, EZH2 is linked to neoplasm.